BioAge Labs, Inc. announced progress in their development pipeline, highlighting the advancement of their oral NLRP3 inhibitor BGE-102, with initial clinical data expected in the second half of 2025.
BioAge Labs (NASDAQ:BIOA) outlined its strategy and near-term clinical plans at Oppenheimer’s 36th Annual Life Science ...
RICHMOND, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic ...
BioAge Labs is having its initial public offering today. The drug developer’s signature product, Azelaprag, isn’t yet on sale, but it is undergoing clinical trials in hopes it will one day be. What ...
BioAge Labs is eyeing around $180 million in initial proceeds from an IPO and a private placement, funds the metabolic-focused biotech will use to push its lead obesity prospect through the clinic.
BioAge Labs' leading candidate is far too early in the process to make reliable predictions. The biotech will encounter plenty of challengers in its chosen therapeutic area. BioAge Labs (NASDAQ: BIOA) ...
BioAge Labs Inc, a biotech focused on developing therapies for metabolic diseases, filed an SEC filing to raise up to $100 million in an initial public offering. The company was founded in 2015 and ...
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming March 10, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit ...
The latest price target for Bioage Labs (NASDAQ:BIOA) was reported by Morgan Stanley on December 8, 2025. The analyst firm set a price target for $12.00 expecting BIOA to fall to within 12 months (a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results